Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» What AbbVie's Recent Drug News Means for Shareholders
What AbbVie's Recent Drug News Means for Shareholders
What AbbVie's Recent Drug News Means for Shareholders
Submitted by
admin
on December 28, 2021 - 10:57am
Source:
Motley Fool
News Tags:
AbbVie
Skyrizi
Crohn’s disease
Europe
Headline:
What AbbVie's Recent Drug News Means for Shareholders
snippet:
Skyrizi was demonstrated to be quite effective in treating Crohn's disease patients in phase 3 clinical trials.
If approved, Skyrizi would gain access to hundreds of thousands of patients in the EU.
AbbVie's valuation and yield are attractive for value and income investors alike.
Do Not Allow Advertisers to Use My Personal information